Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leia Rispoli

Interventional Pain Medicine Marina Del Rey, CA Medical Doctor

NPI 1679993406 CMS profile 5702697

4551 Glencoe Ave Ste 145, Marina Del Rey, CA 90292

Open in the dashboard

General payments

$34,944

526 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leia Rispoli of Marina Del Rey, CA is reported in the CMS Open Payments database as having received $34,944 across 526 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,226 80
2024 General $6,197 86
2023 General $3,646 74
2022 General $1,006 31
2021 General $2,537 94
2020 General $2,724 93
2019 General $5,608 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leia Rispoli
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Leia Rispoli were reported at $13,226. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Leia Rispoli Interventional Pain Medicine median Middle half National median
2019 $5,608 $684 $216–$2,079 $163
2020 $2,724 $382 $122–$1,109 $114
2021 $2,537 $552 $167–$1,554 $132
2022 $1,006 $605 $187–$1,924 $149
2023 $3,646 $671 $195–$1,915 $160
2024 $6,197 $684 $206–$1,837 $164
2025 $13,226 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nalu Medical, Inc. $16,210 69 payments
  2. Boston Scientific Corporation $7,312 207 payments
  3. Medtronic USA, Inc. $3,273 54 payments
  4. Abbott Laboratories $2,295 59 payments
  5. Medtronic, Inc. $1,117 19 payments
  6. Merz Pharmaceuticals, LLC $1,095 32 payments
  7. Nevro Corp. $1,060 14 payments
  8. BIOTRONIK NRO, Inc. $542 16 payments
  9. Curonix LLC $467 11 payments
  10. Brixton Biosciences, Inc. $158 1 payment
  11. Other $1,415 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,856 496 payments
  2. Consulting Fee $9,788 9 payments
  3. Travel and Lodging $5,550 20 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750 1 payment
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $16,210 69 payments
  2. INTELLIS $1,910 20 payments
  3. GENERAL PAIN MANAGEMENT $1,777 65 payments
  4. SPECTRA WAVEWRITER $1,503 12 payments
  5. WaveWriter Alpha Prime 16 $1,154 32 payments
  6. ADAPTIVESTIM $1,138 27 payments
  7. General - Pain Management General - Pain Management_NMD $872 25 payments
  8. Senza Spinal Cord Stimulation System $868 7 payments
  9. GENERAL - PAIN MANAGEMENT Pain Management $737 38 payments
  10. Proclaim IPG $641 17 payments
  11. Other $7,314 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

369

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$3,996

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

14.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 103 $1,308
Duloxetine Hcl Generic 34 $713
Celecoxib Generic 19 $599
Pregabalin Generic 27 $257
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $228
Diclofenac Sodium Generic 15 $217
Tramadol Hcl Generic 41 $137
Methylprednisolone Generic 17 $136
Tizanidine Hcl Generic 18 $135
Cyclobenzaprine Hcl Generic 11 $110

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$200,687

Of which drugs: $666

Medicare patients

430

Average age 75

Services billed

2,679

265 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Ischemic heart disease 32%
Osteoporosis 23%
Depression 21%
Diabetes 19%
Chronic kidney disease 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 73 606 $54
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 73 106 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • Merz Pharmaceuticals, LLC $374
$374 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record